Skip to content
MedsAcross

Medicine

Betamethasone dipropionate and Calcipotriene 0.5 mg/50 mcg per g topical suspension

Available on requestPrescription onlyUS FDAGeneric name

Betamethasone dipropionate and Calcipotriene 0.5 mg/50 mcg per g topical suspension is a generic prescription medicine for topical use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Do not refrigerate. Store between 20°C - 25°C (68°F - 77°F), excursions…

Key facts

Active ingredient (INN)
Betamethasone dipropionate and Calcipotriene
Brand
Sold under the generic name
Strength
0.5 mg/50 mcg per g
Dosage form
Topical suspension
Route
Topical
Packs
1 bottle, 2 bottles
Manufacturer
Cosette Pharmaceuticals
Origin register
US FDA, United States
Storage
Do not refrigerate. Store between 20°C - 25°C (68°F - 77°F), excursions permitted between 15°C - 30°C (59°F - 86°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3004.32Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
2 August 2024
Identifiers
RxCUI 833461DailyMed set ID 1eba330b-ce18-6b12-e063-6294a90a8763NDC 0713-0848Application ANDA210765

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 bottle in 1 carton / 60 g in 1 bottle0713-0848-60Cosette Pharmaceuticals2 August 2024
2 bottle in 1 carton / 60 g in 1 bottle0713-0848-92Cosette Pharmaceuticals2 August 2024

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 9 January 2006Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Betamethasone dipropionate and Calcipotriene 0.5 mg/50 mcg per g topical suspension.

Compare 1

Other strengths and forms of Betamethasone dipropionate and Calcipotriene

Clinical summary

Betamethasone dipropionate and Calcipotriene is a fixed-dose combination of a corticosteroid and a vitamin D analog indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. MedsAcross supplies Betamethasone dipropionate and Calcipotriene for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Betamethasone dipropionate and Calcipotriene

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Betamethasone dipropionate and Calcipotriene 0.5 mg/50 mcg per g topical suspension for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.